The FDA granted approval to Merck's monoclonal antibody drug Enflonsia for preventing respiratory syncytial virus (RSV) infections in infants under 12 months. The drug is priced competitively against existing treatments and is expected to influence the pediatric RSV prevention landscape. However, the CDC’s Advisory Committee on Immunization Practices, which advises on RSV vaccine use, was abruptly dismissed, raising questions about the committee’s future recommendations.